First, it was recently shown that oncogenic KRAS-induced NRF2 upregulates glutaminolysis, which promotes chemoresistance in PDAC [14,33]; however, we were unable to explore the role of NRF2 in cancer metabolism in the present study. This evidence concerns the gene KRAS and cancer.